By Fineline Cube 
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its IMC-003/IMM72 in pulmonary arterial hypertension (PAH).
Drug Profile
IMC-003/IMM72 is a next-generation activator receptor IIA Fc type (ActRIIA Fc) fusion protein that has been genetically modified. It is designed with higher activity and quality to address the needs of patients with PAH.
Intellectual Property and Rights
ImmuneOnco Biopharmaceuticals owns the global intellectual property and development and commercialization rights to the drug candidate IMC-003/IMM72.-Fineline Info & Tech